Currently, there are 66.80M common shares owned by the public and among those 56.99M shares have been available to trade.
Insiders at the company have transacted a total of 40 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 520,950 shares. Insider sales of the common stock occurred on 18 occasions, with total insider shares sold totaling 373,400 shares.
However, the script later moved the day high at 37.90, up 2.44%. The company’s stock has a 5-day price change of -4.16% and 30.96% over the past three months. CRNX shares are trading 6.30% year to date (YTD), with the 12-month market performance up to 89.38% higher. It has a 12-month low price of $15.23 and touched a high of $40.50 over the same period. CRNX has an average intraday trading volume of 800.11K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.35%, 4.69%, and 42.63% respectively.
Institutional ownership of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) shares accounts for 101.29% of the company’s 66.80M shares outstanding.
It has a market capitalization of $2.53B and a beta (3y monthly) value of 0.60. The earnings-per-share (ttm) stands at -$3.64. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.06% over the week and 4.04% over the month.
Analysts forecast that Crinetics Pharmaceuticals Inc (CRNX) will achieve an EPS of $Cerence Inc. for the current quarter, $15.57 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Ceragon Networks Ltd. while analysts give the company a high EPS estimate of $Cognex Corporation. Comparatively, EPS for the current quarter was $Century Aluminum Company a year ago. Earnings per share for the fiscal year are expected to decrease by -13.62%, and 4.36% over the next financial year.
Looking at the support for the CRNX, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on January 16, 2024, with the firm’s price target at $50.
